Evidence map›Paper›PMID 32108022›Full record

Trial reportDiabetes care2020

Medication Adherence During Adjunct Therapy With Statins and ACE Inhibitors in Adolescents With Type 1 Diabetes.

Elżbieta Niechciał, Carlo L Acerini, Scott T Chiesa, Tracey Stevens, R Neil Dalton, Denis Daneman, John E Deanfield, Timothy W Jones, Farid H Mahmud, Sally M Marshall and 5 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Review
  5. Review
  6. Great Drugs, If You Could Just Get Patients to Take Them.Cardiovascular drugs and therapy · 2023
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Elżbieta NiechciałDepartment of Pediatric Diabetes, Endocrinology and Obesity, Poznan University of Medical Sciences, Poznan, Poland.ORCID 0000-0003-3245-8131
Carlo L AceriniDepartment of Paediatrics, University of Cambridge, Cambridge, U.K.
Scott T ChiesaInstitute of Cardiovascular Science, University College London, London, U.K.
Tracey StevensDepartment of Paediatrics, University of Cambridge, Cambridge, U.K.
R Neil DaltonEvelina Children's Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London, U.K.
Denis DanemanDepartment of Paediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.
John E DeanfieldInstitute of Cardiovascular Science, University College London, London, U.K.
Timothy W JonesTelethon Kids Institute, The University of Western Australia, Perth, Australia.ORCID 0000-0002-7989-1998
Farid H MahmudDepartment of Paediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-3557-3584
Sally M MarshallInstitute of Cellular Medicine (Diabetes), Faculty of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, U.K.
H Andrew W NeilOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, U.K.
David B DungerDepartment of Paediatrics, University of Cambridge, Cambridge, U.K.ORCID 0000-0002-2566-9304
M Loredana MarcovecchioORCID 0000-0002-4415-316X
Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) Study Group
Adolescent Type 1 Diabetes Cardio-renal Intervention Trial AdDIT Study Group
University of Cambridge · GBUniversity College London · GBUniversity of Toronto · CANewcastle University · GBThe Kids Research Institute Australia · AUUniversity of Oxford · GBGuy's and St Thomas' NHS Foundation Trust · GBPoznan University of Medical Sciences · PL

Funding

British Heart Foundation PG/19/31/34343Diabetes UK 06/0003341Diabetes UK 12/0004468
6 · The paper itself

Abstract

objectiveSuboptimal adherence to insulin treatment is a main issue in adolescents with type 1 diabetes. However, to date, there are no available data on adherence to adjunct noninsulin medications in this population. Our aim was to assess adherence to ACE inhibitors and statins and explore potential determinants in adolescents with type 1 diabetes. RESEARCH DESIGN AND

methodsThere were 443 adolescents with type 1 diabetes recruited into the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) and exposed to treatment with two oral drugs-an ACE inhibitor and a statin-as well as combinations of both or placebo for 2-4 years. Adherence was assessed every 3 months with the Medication Event Monitoring System (MEMS) and pill count.

resultsMedian adherence during the trial was 80.2% (interquartile range 63.6-91.8) based on MEMS and 85.7% (72.4-92.9) for pill count. Adherence based on MEMS and pill count dropped from 92.9% and 96.3%, respectively, at the first visit to 76.3% and 79.0% at the end of the trial. The percentage of study participants with adherence ≥75% declined from 84% to 53%. A good correlation was found between adherence based on MEMS and pill count (

conclusionsWe report an overall good adherence to ACE inhibitors and statins during a clinical trial, although there was a clear decline in adherence over time. Older age and suboptimal glycemic control at baseline predicted lower adherence during the trial, and, predictably, reduced adherence was more prevalent in subjects who subsequently dropped out.

Indexed as

Drug MonitoringAdolescentAngiotensin-Converting Enzyme InhibitorsAustraliaCanadaCardiovascular DiseasesChemotherapy, AdjuvantChildDiabetes Mellitus, Type 1Diabetic AngiopathiesDouble-Blind MethodDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInsulinAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin

Identifiers

PMID32108022
PMCPMC7282885
OpenAlexW3007888419

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.